• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Therapeutic Proteins Oral Vaccines Market

    ID: MRFR/Pharma/26212-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Therapeutic Proteins And Oral Vaccines Market Research Report By Therapeutic Class (Antibodies, Enzymes, Hormones, Growth factors, Polypeptides), By Vaccine Type (Live attenuated, Inactivated, Toxoid, Subunit, Conjugate), By Disease Indication (Cancer, Cardiovascular diseases, Autoimmune diseases, Infectious diseases, Neurological disorders), By Route of Administration (Intravenous, Subcutaneous, Intramuscular, Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Therapeutic Proteins Oral Vaccines Market Infographic
    Purchase Options

    Therapeutic Proteins Oral Vaccines Market Summary

    The Global Therapeutic Proteins and Oral Vaccines Market is projected to grow significantly from 222.83 USD Billion in 2024 to 554.00 USD Billion by 2035.

    Key Market Trends & Highlights

    Therapeutic Proteins And Oral Vaccines Key Trends and Highlights

    • The market is expected to witness a compound annual growth rate (CAGR) of 8.63 percent from 2025 to 2035.
    • By the year 2035, the market valuation is anticipated to reach 554.0 USD Billion, indicating robust growth potential.
    • in 2024, the market is valued at 222.83 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of innovative therapeutic proteins due to increasing prevalence of chronic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 222.83 (USD Billion)
    2035 Market Size 554.00 (USD Billion)
    CAGR (2025-2035) 8.63%

    Major Players

    GSK, AbbVie Biopharmaceuticals, Roche, Genentech, Pfizer, Eli Lilly, Amgen, Merck Sharp Dohme, Bayer HealthCare, AstraZeneca, Novartis, Johnson Johnson, Sanofi Aventis, Biogen

    Therapeutic Proteins Oral Vaccines Market Trends

    The rising prevalence of chronic diseases fuels demand for therapeutic proteins and oral vaccines. Advancements in biotechnology, such as genetic engineering and cell culture technologies, enhance the efficacy and production efficiency of these products.Growing government initiatives and funding support research and development in this field, particularly in developing countries. Additionally, increasing healthcare expenditure and the expansion of healthcare coverage contribute to market growth. The shift towards personalized medicine, where therapies are tailored to individual patient needs, drives the development of targeted therapeutic proteins and oral vaccines.

    Furthermore, partnerships and collaborations between pharmaceutical companies and research institutions accelerate innovation and bring new products to market.

    The ongoing advancements in biopharmaceutical technologies are likely to enhance the efficacy and accessibility of therapeutic proteins and oral vaccines, potentially transforming healthcare delivery on a global scale.

    U.S. Food and Drug Administration (FDA)

    Therapeutic Proteins Oral Vaccines Market Drivers

    Market Growth Projections

    Advancements in Biotechnology

    Technological innovations in biotechnology significantly contribute to the growth of the Global Therapeutic Proteins And Oral Vaccines Market Industry. The development of novel protein engineering techniques and expression systems has led to the creation of more effective and safer therapeutic proteins. For instance, the use of recombinant DNA technology has revolutionized the production of therapeutic proteins, allowing for higher yields and improved quality. As a result, the market is poised for expansion, with projections indicating a rise to 554.0 USD Billion by 2035. This growth is further supported by ongoing research and development efforts aimed at enhancing the therapeutic potential of proteins.

    Regulatory Support for Biologics

    Regulatory bodies worldwide are providing increased support for the development and approval of biologics, including therapeutic proteins and oral vaccines. Streamlined approval processes and guidelines facilitate faster market entry for innovative products. The Global Therapeutic Proteins And Oral Vaccines Market Industry benefits from these regulatory advancements, as they encourage companies to invest in research and development. This supportive environment is likely to enhance the availability of new therapies, ultimately improving patient access to cutting-edge treatments. As regulations evolve, the market is expected to expand, reflecting the growing recognition of the importance of biologics in modern medicine.

    Increasing Demand for Oral Vaccines

    The demand for oral vaccines is on the rise due to their ease of administration and potential for improved patient compliance. The Global Therapeutic Proteins And Oral Vaccines Market Industry is witnessing a shift towards oral formulations, particularly for vaccines targeting infectious diseases. Oral vaccines can simplify vaccination processes, especially in low-resource settings, thereby enhancing public health outcomes. As the global population continues to grow, the need for effective vaccination strategies becomes more pressing. This trend is likely to drive market growth, as oral vaccines offer a viable alternative to traditional injectable vaccines, potentially increasing vaccination rates worldwide.

    Rising Prevalence of Chronic Diseases

    The increasing incidence of chronic diseases such as diabetes, cancer, and autoimmune disorders drives demand for therapeutic proteins. These proteins, which include monoclonal antibodies and insulin, are crucial in managing these conditions. The Global Therapeutic Proteins And Oral Vaccines Market Industry is expected to witness substantial growth as healthcare systems adapt to the rising burden of chronic illnesses. In 2024, the market is projected to reach 222.8 USD Billion, reflecting a growing recognition of the importance of protein-based therapies in improving patient outcomes. This trend is likely to continue, as advancements in biotechnology enhance the efficacy of these treatments.

    Growing Investment in Biopharmaceutical Research

    Investment in biopharmaceutical research is a critical driver of the Global Therapeutic Proteins And Oral Vaccines Market Industry. Governments and private entities are increasingly funding research initiatives aimed at discovering and developing new therapeutic proteins and vaccines. This influx of capital supports innovative projects that may lead to breakthroughs in treatment options for various diseases. As a result, the market is expected to grow at a compound annual growth rate (CAGR) of 8.63% from 2025 to 2035. This sustained investment not only fosters innovation but also enhances the overall competitiveness of the biopharmaceutical sector on a global scale.

    Market Segment Insights

    Therapeutic Proteins And Oral Vaccines Market Segment Insights

    Therapeutic Proteins And Oral Vaccines Market Segment Insights

    Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Insights

    Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Insights

    The Therapeutic Proteins And Oral Vaccines Market is segmented into various classes based on therapeutic applications. Some of the key therapeutic classes in the market include antibodies, enzymes, hormones, growth factors and polypeptides. Each class has its unique characteristics and applications, contributing to the overall growth of the Therapeutic Proteins And Oral Vaccines Market. Antibodies accounted for the largest therapeutic Proteins And Oral Vaccines Market share in 2023, and this trend is expected to continue during the forecast period.Antibodies are proteins produced by the immune system to neutralize pathogens and toxins.

    They play a crucial role in treating various diseases, including cancer, autoimmune disorders and infectious diseases. Enzymes are proteins that catalyze chemical reactions in the body. They are used in various therapeutic applications, such as enzyme replacement therapy for genetic disorders and digestive enzyme supplements. The increasing prevalence of chronic diseases, such as diabetes and cancer, is driving the demand for enzyme-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market.Hormones are proteins that regulate various physiological processes in the body.

    They are used in hormone replacement therapy for conditions such as menopause, growth hormone deficiency, and thyroid disorders. The growing geriatric population and the increasing incidence of hormone-related disorders are expected to fuel the demand for hormone-based therapeutics, propelling the growth of the Therapeutic Proteins And Oral Vaccines Market. Growth factors are proteins that stimulate cell growth and proliferation.

    They are used in various therapeutic applications, including wound healing, bone regeneration, and tissue engineering.Advances in biotechnology and regenerative medicine are expected to drive the demand for growth factor-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market. Polypeptides are short chains of amino acids that have various therapeutic applications. They are used in antibiotics, hormones, and other therapeutic agents. The increasing demand for targeted therapies and the development of novel polypeptide-based drugs are expected to drive the growth of the Therapeutic Proteins And Oral Vaccines Market.

    Therapeutic Proteins And Oral Vaccines Market Vaccine Type Insights

    Therapeutic Proteins And Oral Vaccines Market Vaccine Type Insights

    The Therapeutic Proteins And Oral Vaccines Market is segmented into five types of vaccines, namely, live attenuated, inactivated, toxoid, subunit, and conjugate. Among these segments, the subunit vaccines segment is expected to hold the largest market share in 2023 and is projected to grow at a CAGR of 8.63% from 2024 to 2034. Subunit vaccines are composed of purified pieces of a pathogen, such as a protein or polysaccharide.

    Since they do not contain any live or inactivated virus or bacteria, they are safer than live attenuated or inactivated vaccines and are less likely to cause side effects.The live attenuated vaccines segment is the second largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034. Live attenuated vaccines are made from a weakened form of the pathogen and offer long-lasting immunity. However, they can also cause side effects, such as fever and rash.

    The inactivated vaccines segment is the third largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034. Inactivated vaccines are made from a killed form of the pathogen and are less likely to cause side effects than live attenuated vaccines.However, they may not provide long-lasting immunity. The toxoid vaccines segment is the fourth largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.63% from 2024 to 2034.

    Toxoid vaccines are made from a toxin that has been chemically modified to make it harmless. They are used to prevent diseases such as tetanus and diphtheria. The conjugate vaccines segment is the fifth largest segment in the Therapeutic Proteins And Oral Vaccines Market.

    Therapeutic Proteins And Oral Vaccines Market Disease Indication Insights

    Therapeutic Proteins And Oral Vaccines Market Disease Indication Insights

    The Disease Indication segment of the Therapeutic Proteins And Oral Vaccines Market is expected to grow significantly in the coming years. Key drivers of this growth include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, autoimmune diseases, infectious diseases and neurological disorders. The Therapeutic Proteins And Oral Vaccines Market for Cancer is expected to reach a valuation of USD 152.3 billion by 2023, growing at a CAGR of 8.4%.

    The Cardiovascular diseases segment is also expected to witness significant growth, reaching a valuation of USD 72.6 billion by 2024, growing at a CAGR of 7.9%.The Autoimmune diseases segment is expected to reach a valuation of USD 55.4 billion by 2023, growing at a CAGR of 7.6%. The Infectious diseases segment is expected to reach a valuation of USD 48.3 billion by 2023, growing at a CAGR of 7.2%. The Neurological disorders segment is expected to reach a valuation of USD 39.2 billion by 2034, growing at a CAGR of 6.9%.

    Therapeutic Proteins And Oral Vaccines Market Route of Administration Insights

    Therapeutic Proteins And Oral Vaccines Market Route of Administration Insights

    The route of administration segment in the Therapeutic Proteins And Oral Vaccines Market is segmented into intravenous, subcutaneous, intramuscular, oral and topical. Intravenous administration is expected to hold the largest market share in 2023 due to the ease of administration and the ability to deliver drugs directly into the bloodstream. Subcutaneous administration is expected to grow at the highest CAGR during the forecast period due to the increasing use of self-injection devices.

    The oral route of administration is expected to account for a significant share of the market due to the convenience and ease of administration.The topical route of administration is expected to grow at a moderate CAGR during the forecast period due to the increasing use of topical therapies for the treatment of skin diseases.

    Get more detailed insights about Therapeutic Proteins Oral Vaccines Market

    Regional Insights

    The Therapeutic Proteins And Oral Vaccines Market is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second-largest region, followed by Asia Pacific. The APAC region is expected to grow at the highest CAGR during the forecast period, driven by factors such as rising disposable income, increasing healthcare expenditure, and the growing prevalence of chronic diseases.

    The South American and MEA regions are also expected to witness significant growth during the forecast period.The growth of the Therapeutic Proteins And Oral Vaccines Market is attributed to factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in the field of biotechnology. The market is also benefiting from government initiatives and support for the development and production of therapeutic proteins and oral vaccines.

    Therapeutic Proteins And Oral Vaccines Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The major players in the Therapeutic Proteins And Oral Vaccines Market industry are taking various measures to maintain their positions and expand their market share. For example, in March 2023, Pfizer Inc. acquired Arena Pharmaceuticals, which is a clinical-stage biopharmaceutical company, in order to bolster its immunology and inflammation research and development. Moreover, in June 2023, Gilead Sciences Inc. reached an agreement with Arcus Biosciences, Inc. to jointly discover, develop and commercialize cancer-related novel immunotherapies. These measures are projected to foster growth in the Therapeutic Proteins And Oral Vaccines Market industry.

    One of the leading players in the Therapeutic Proteins And Oral Vaccines Market is Pfizer Inc. The company, which is headquartered in New York City, is a research-based global Biopharmaceutical company. It develops and manufactures vaccines and other medicines. Pfizer boasts a number of promising therapeutic proteins and oral vaccines in its pipeline. For instance, it will soon start mass production of Comirnaty, which is an mRNA type vaccine for COVID-19. Its leading position is supported by Pfizer’s strong R&D capabilities and worldwide presence.

    The company has formed a range of agreements with biotech companies in order to promote the arrival of new drugs.

    Therefore, one of the main competitors is Moderna, Inc., which is a biotechnology company based in Cambridge, Massachusetts. The company focuses on existing mRNA-based therapeutics and vaccines. Its mRNA COVID-19 vaccine Spikevax has been widely used worldwide. Furthermore, it is currently developing other therapeutics for a number of diseases, such as cancer, cardiovascular diseases, rare diseases and others. Based on the innovative technology platform and promising pipeline, Moderna, Inc. is a significant competitor in the Therapeutic Proteins And Oral Vaccines Market.

    Key Companies in the Therapeutic Proteins Oral Vaccines Market market include

    Industry Developments

    The Therapeutic Proteins And Oral Vaccines Market is projected to reach USD 509.98 billion by 2034, exhibiting a CAGR of 8.63% during the forecast period (2025-2034). The market growth is attributed to the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in protein engineering and vaccine development.

    Key recent developments include the approval of novel therapeutic proteins such as Hemlibra and Evrysdi and the ongoing development of mRNA-based oral vaccines for infectious diseases. Major players in the market include AbbVie, Amgen, and Pfizer, who are investing in research and development to expand their product portfolios and address unmet medical needs.

    Future Outlook

    Therapeutic Proteins Oral Vaccines Market Future Outlook

    The Global Therapeutic Proteins and Oral Vaccines Market is projected to grow at an 8.63% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands.

    New opportunities lie in:

    • Develop personalized therapeutic proteins targeting specific diseases.
    • Invest in oral vaccine delivery systems to enhance patient compliance.
    • Leverage AI for rapid drug discovery and development processes.

    By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare landscapes.

    Market Segmentation

    Therapeutic Proteins And Oral Vaccines Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Therapeutic Proteins And Oral Vaccines Market Vaccine Type Outlook

    • Live attenuated
    • Inactivated
    • Toxoid
    • Subunit
    • Conjugate

    Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Outlook

    • Antibodies
    • Enzymes
    • Hormones
    • Growth factors
    • Polypeptides

    Therapeutic Proteins And Oral Vaccines Market Disease Indication Outlook

    • Cancer
    • Cardiovascular diseases
    • Autoimmune diseases
    • Infectious diseases
    • Neurological disorders

    Therapeutic Proteins And Oral Vaccines Market Route of Administration Outlook

    • Intravenous
    • Subcutaneous
    • Intramuscular
    • Oral
    • Topical

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024  222.83 (USD Billion)
    Market Size 2025  242.06 (USD Billion)
    Market Size 2035 554.00 (USD Billion)
    Compound Annual Growth Rate (CAGR) 8.63% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2020 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled GSK, AbbVie Biopharmaceuticals, RocheGenentech, Pfizer, Eli Lilly, Amgen, Merck Sharp Dohme, Bayer HealthCaren, AstraZeneca, Genentech, Novartis, Johnson Johnson, SanofiAventis, Biogen
    Segments Covered Therapeutic Class, Vaccine Type, Disease Indication, Route of Administration, Regional
    Key Market Opportunities 1.       Rising prevalence of chronic diseases 2.       Increasing demand for personalized medicine 3.       Technological advancements in drug delivery systems 4.       Growing investments in RampD 5.       Government initiatives promoting innovation
    Key Market Dynamics 1 Rising prevalence of chronic diseases2 Technological advancements in protein engineering3 Increasing government funding4 Growth of emerging markets5 Expanding applications in personalized medicine
    Countries Covered North America, Europe, APAC, South America, MEA

    FAQs

    What is the projected growth of the Therapeutic Proteins And Oral Vaccines market?

    The Therapeutic Proteins And Oral Vaccines market is the expected increase in total market value of 554 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Therapeutic Proteins And Oral Vaccines market?

    Therapeutic Proteins And Oral Vaccines market size was valued at approximately 222.83 billion USD in 2024. This figure will reach 554 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Therapeutic Proteins And Oral Vaccines market?

    Therapeutic Proteins And Oral Vaccines market is expected to grow at a CAGR of 8.63% between 2025 and 2035.

    How much will the Therapeutic Proteins And Oral Vaccines market be worth by 2035?

    Therapeutic Proteins And Oral Vaccines market is expected to be worth of 554 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Therapeutic Proteins And Oral Vaccines market perform over the next 10 years?

    Over the next 10 years the Therapeutic Proteins And Oral Vaccines market is expected to shift from usd billion 222.83 to 554 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region is expected to hold the largest market share in the Therapeutic Proteins And Oral Vaccines Market in 2024?

    North America is expected to hold the largest market share in the Therapeutic Proteins And Oral Vaccines Market in 2024.

    Which application segment is expected to hold the largest market share in the Therapeutic Proteins And Oral Vaccines Market in 2024?

    The oncology segment is expected to hold the largest market share in the Therapeutic Proteins And Oral Vaccines Market in 2024.

    Who are some of the key competitors in the Therapeutic Proteins And Oral Vaccines Market?

    Some of the key competitors in the Therapeutic Proteins And Oral Vaccines Market include Amgen, AbbVie, Roche, Pfizer, and Merck.

    What are the key factors driving the growth of the Therapeutic Proteins And Oral Vaccines Market?

    The key factors driving the growth of the Therapeutic Proteins And Oral Vaccines Market include the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and the technological advancements in the field of biotechnology.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials